Shaffer Grants

Logo
Glaucoma Research Foundation

Glaucoma Research Foundation (GRF) provides seed money for creative pilot research projects that hold promise.

 

Known as “Shaffer Grants for Innovative Glaucoma Research” in honor of GRF founder Dr. Robert N. Shaffer, the Shaffer Grants continue our longstanding commitment to one-year incubation grants to explore novel and promising ideas in the study of glaucoma.

The National Institutes of Health and large companies may pass over the young researcher with an

innovative idea, if there is no precedent. Armed with evidence made possible by our research grants,

scientists can often secure the major funding necessary to bring their ideas to fruition.

 

Strategic Research Goals

 

  • Protect and restore the optic nerve
  • Accurately detect glaucoma and monitor its progress
  • Find the genes responsible for glaucoma
  • Understand the intraocular pressure system and develop better treatments
  • Determine the risk factors for glaucoma damage using systematic outcomes data

 

Core Values

 

  • Involve people with glaucoma in the design, implementation and evaluation of programs.
  • Encourage collaboration among experts in many fields of study to achieve GRF goals.
  • Communicate research goals and results to the scientific community and the public.
  • Ensure that new glaucoma treatments maintain or improve individuals’ quality of life.
  • Encourage innovative clinical trial studies and laboratory research.
  • Develop cell and animal models of glaucoma to support research studies.
  • Facilitate and support the development of physician-scientists to advance glaucoma research.

 

DEADLINES & Vergabeordnung
Submission Deadline 15.07.2019
Vergabeordnung https://www.glaucoma.org/research/applying-for-a-grant.php
Dotation

50,000 $

Interval
yearly
Bisherige Preiseträger

 

2019: 

Steven Barnes, PhD; Project: Functional Resilience of Retinal Ganglion Cells During Mitochondrial Dysfunction

Adnan Dibas, PhD; Project: Endothelin Converting Enzyme Knockdown is Neuroprotective in Glaucomatous Neuropathy

Ankur Jain, PhD; Project: Autophagy-targeted Treatment for Myocilin-associated Glaucoma

Pierre Mattar, MSc, PhD; Project: Programming and Reprogramming for Retinal Ganglion Cell Replacement Therapy

Lauren Katie Wareham, PhD; Project: Investigating the Role of the NO-GC-1-cGMP Signaling Pathway in Glaucoma

Pete A. Williams, PhD; Project: Targeting Neuronal Mitochondria for Neuroprotection in Glaucoma

Contact
251 Post Street, Suite 600
San Francisco, CA 94108
(415) 986-3162
(800) 826-6693
research@glaucoma.org
030 / 920 3854 262